IAVI
Develops affordable vaccines and antibodies for global infectious diseases.
Company facts
- Founded
- 1996
- Employees
- 375
- Headquarters
- United States
- CEO
- Mark Feinberg
- Type
- Non-Profit
About
IAVI is a nonprofit scientific research organization that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. Founded in 1996, IAVI has established itself as a leader in vaccine development, championing initiatives and partnerships that make scientific discoveries a reality for global health. The organization focuses on the translation of scientific innovations into affordable and globally accessible public health solutions. At IAVI, diversity, equity, and inclusion are central to the mission, ensuring that all voices contribute to the fight against infectious diseases. IAVI operates in various regions, including Africa, Europe, and India, underscoring its global commitment. The organization has been integral to the development of innovative vaccine candidates, engaging with various stakeholders from governments to the private sector. Alongside research, IAVI emphasizes the importance of engagement and education, enhancing understanding of the diseases it targets. The impact of IAVI's work can be seen in the ongoing clinical trials and the partnerships formed that drive medical innovation forward, making strides towards ending the HIV epidemic and providing solutions for other infectious disease challenges.